China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai

Adlai Nortye Biopharma of Hangzhou acquired global rights to a novel immuno-oncology oral EP4 antagonist developed by Japan's Eisai Co. Eisai has reported positive results from a Phase I test of the drug in Japan, where it will retain rights. Adlai Nortye will have exclusive worldwide research, development, manufacturing and commercialization rights to E7046, excluding Japan and some other Asian countries, though it will have rights for Mainland China. Financial details of the agreement were not disclosed. More details....

Stock Symbol: (NEEQ: 870946)

Share this with colleagues:

Original Article: China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai

More From BioPortfolio on "China's Adlai Nortye Acquires Immuno-oncology Candidate from Eisai"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications